GlassScriptPhysician profile
Wai P Chan
NPI 1033354428
$5,279.81
in general payments reported to CMS, 2019-2025
22 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2021: $160 · 2022: $1,305 · 2023: $1,323 · 2024: $1,168 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,455 · Education: $87.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,454.99 |
| Education | $87.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $717.72 | 2023-2024 | Vtama |
| Pfizer INC. | $631.13 | 2021-2025 | |
| Incyte Corporation | $532.42 | 2021-2025 | Opzelura |
| Genzyme Corporation | $436.01 | 2021-2024 | |
| Galderma Laboratories, L.P. | $402.52 | 2022-2024 | Aklief |
| Leo Pharma INC. | $314.82 | 2024-2025 | Anzupgo, Adbry |
| Janssen Biotech, INC. | $297.70 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $268.43 | 2022-2023 | Winlevi, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $262.11 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $232.77 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $215.05 | 2022-2025 | Dupixent |
| Epi Health, LLC | $179.72 | 2022 | |
| Lilly USA, LLC | $158.30 | 2022-2025 | Ebglyss, Taltz |
| Abbvie INC. | $147.97 | 2019-2025 | |
| Ucb, INC. | $102.74 | 2021-2024 | Bimzelx |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $96.38 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $81.28 | 2022-2023 | Targretin |
| Gilead Sciences, INC. | $69.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $41.87 | 2022-2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.48 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Amgen INC. | $21.22 | 2023 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wai Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.